March 30, 2010 (FinancialWire) — Tianyin Pharmaceutical Co., Inc., (NYSE: TPI), a manufacturer and supplier of modernized traditional Chinese medicine, said it has appointed James Jiayuan Tong as its chief financial officer and Chief Business & Development officer, effective April 1. In addition, Tong will join the company's board of directors on April 1.

Prior to joining Tianyin, Tong was the Head of China Healthcare Investment Banking at ROTH Capital Partners, Newport Beach, California. He initially joined ROTH as an equity research analyst, spearheading the firm’s effort in China healthcare, covering a series of U.S.-listed Chinese pharmaceutical, biotech, medical devices and drug retail businesses.

Prior to that, Tong was a biotechnology analyst at Rodman & Renshaw, New York, covering biotech entities focusing on molecular diagnostics and cures for Alzheimer's disease, multiple sclerosis and cancer.

Before his Wall Street career, Tong was Principal Investigator at Marine Biological Laboratory sponsored by Grass Foundation at Woods Hole, Massachusetts and a Senior Research Fellow at University of California, Irvine.

China-based Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine in China. It was established in 1994 and acquired by the current management team in August 2003.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.